Respiratory syncytial virus (RSV)-approved monoclonal antibody Palivizumab as ligand for anti-idiotype nanobody-based synthetic cytokine receptors

Ettich J, Wittich C, Moll J, Behnke K, Floss D, Reiners J, Christmann A, Lang P, Smits S, Kolmar H, Scheller J
Journal of Biological Chemistry :105270 (2023 Sep)

doi: 10.1016/j.jbc.2023.105270 		Submitted to SASBDB: 2023 Jun 22
Published in SASBDB:

SASDSU6 – Palivizumab IgG

Palivizumab IgG experimental SAS data
CORAL model
Sample: Palivizumab IgG monomer, 145 kDa Commercial (Synagis) protein
Buffer: PBS (137 mM NaCl, 2.7 mM KCl, 12 mM HPO4 2−/H2PO4 −), pH: 7.4
Experiment: SAXS data collected at EMBL P12, PETRA III on 2022 Sep 14
RgGuinier 5.0 nm
Dmax 16.8 nm
VolumePorod 252 nm3

SASDSV6 – Nanobody AIP1 VHH

Anti-Idiotypic-Palivizumab-Nanobody1 experimental SAS data
CORAL model
Sample: Anti-Idiotypic-Palivizumab-Nanobody1 monomer, 20 kDa Lama glama protein
Buffer: PBS (137 mM NaCl, 2.7 mM KCl, 12 mM HPO4 2−/H2PO4 −), pH: 7.4
Experiment: SAXS data collected at EMBL P12, PETRA III on 2022 Sep 14
RgGuinier 2.6 nm
Dmax 8.8 nm
VolumePorod 31 nm3

SASDSW6 – Palivizumab Nanobody AIP1VHH complex

Palivizumab IgGAnti-Idiotypic-Palivizumab-Nanobody1 experimental SAS data
CORAL model
Sample: Palivizumab IgG monomer, 145 kDa Commercial (Synagis) protein
Anti-Idiotypic-Palivizumab-Nanobody1 monomer, 20 kDa Lama glama protein
Buffer: PBS (137 mM NaCl, 2.7 mM KCl, 12 mM HPO4 2−/H2PO4 −), pH: 7.4
Experiment: SAXS data collected at EMBL P12, PETRA III on 2022 Sep 14
RgGuinier 6.0 nm
Dmax 20.4 nm